Impax Laboratories, Inc.
IPXL
IPXL was delisted on the 4th of May, 2018.
200 hedge funds and large institutions have $1.24B invested in Impax Laboratories, Inc. in 2017 Q4 according to their latest regulatory filings, with 48 funds opening new positions, 71 increasing their positions, 51 reducing their positions, and 35 closing their positions.
346% more call options, than puts
Call options by funds: $1.41M | Put options by funds: $315K
39% more repeat investments, than reductions
Existing positions increased: 71 | Existing positions reduced: 51
37% more first-time investments, than exits
New positions opened: 48 | Existing positions closed: 35
6% more funds holding
Funds holding: 189 → 200 (+11)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
10% less capital invested
Capital invested by funds: $1.38B → $1.24B (-$135M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$75.8M |
| 2 |
TG
TCW Group
Los Angeles,
California
|
+$35.5M |
| 3 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$31.5M |
| 4 |
GKIM
GW&K Investment Management
Boston,
Massachusetts
|
+$20.3M |
| 5 |
MC
Maverick Capital
Dallas,
Texas
|
+$15.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$20.4M |
| 2 |
BlackRock
New York
|
-$14.6M |
| 3 |
BIM
Bogle Investment Management
Newton Lower Falls,
Massachusetts
|
-$12.4M |
| 4 |
BM
Bridger Management
New York
|
-$12.2M |
| 5 |
ECP
Empyrean Capital Partners
Los Angeles,
California
|
-$10.5M |
IPXL Hedge Fund Activity: Q4 2017 in Review
200 of the 4,410 institutional investors tracked by Wall St. Rank reported a position in Impax Laboratories, Inc. (IPXL) for Q4 2017, worth a combined $1.24B — down 9.8% from $1.38B a quarter earlier.
Buyers outnumbered sellers: 48 funds opened new IPXL positions and 35 closed out — a net gain of 13 holders — while 71 added to existing stakes and 51 trimmed.
The largest buyer was Wellington Management Group, opening a new position worth an estimated $75.8M. The largest seller was Point72 Asset Management, exiting entirely with an estimated $20.4M sold.
- 200 institutional investors held Impax Laboratories, Inc. (IPXL) as of Q4 2017, up from 189 in Q3 2017.
- Funds reported $1.24B of Impax Laboratories, Inc. stock for Q4 2017, down 9.8% quarter-over-quarter.
- 48 funds opened new Impax Laboratories, Inc. positions in Q4 2017 and 35 closed out, a net change of +13 holders.
- The largest Impax Laboratories, Inc. buyer in Q4 2017 was Wellington Management Group, an estimated $75.8M added.
- The largest Impax Laboratories, Inc. seller in Q4 2017 was Point72 Asset Management, an estimated $20.4M sold.
Based on aggregated 13F filings for Q4 2017.